Dyne Therapeutics

Join us at the RNA Therapeutics Symposium 2025, where Oxana Beskrovnaya, Dyne’s Chief Innovation Officer, will share how the FORCE™ platform was designed to deliver targeted therapeutics to muscle and CNS to provide functional improvement for people with neuromuscular diseases. Learn more and register: https://bit.ly/3J7ihv3

Healthcare policies should help – not hinder – access to much-needed care. We partnered with Myotonic Dystrophy Foundation and Engage Health, Inc. to better understand the challenges faced by individuals living with myotonic dystrophy type 1 (DM1) when navigating healthcare coverage so that we may help improve access and support. Our findings are featured at #NORDSummit2025. See below and learn more here: https://bit.ly/4ora17V

We were thrilled to welcome Kathleen Tregoning for our FORCEs in Biotech series. Kathleen shared insights from her time on the Hill and her approach to external engagement. “Government affairs isn't bowling. It's billiards. Every conversation with policymakers, investors, and advocacy groups shapes the next. Influence starts early—long before the headlines.” Her perspective reminds us that how we show up matters, and that influence is built through thoughtful and deliberate engagement. Thank you, Kathleen, for your time and valuable insights!

We're pleased to introduce the international nonproprietary names for Dyne’s lead candidates for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD): 🔹DYNE-101 is now zeleciment basivarsen for DM1 🔹DYNE-251 is now zeleciment rostudirsen for DMD Both candidates are designed to deliver functional improvement for people living with genetically driven neuromuscular diseases. Learn more about our programs: https://bit.ly/4gKy9zI

Data from the ongoing Phase 1/2 ACHIEVE trial in myotonic dystrophy type 1 (DM1) to be presented at the Congress of the World Muscle Society continue to demonstrate a favorable safety and efficacy profile for zeleciment basivarsen (z-basivarsen, formerly known as DYNE-101). New results, including patient- and physician-reported outcomes, also show that improvements in function, strength and overall disease burden are recognized and meaningful. Learn more about the findings and see all of our presentations: https://bit.ly/4gXSQbu #WMS2025

Next week, we’ll be at the International Congress of the World Muscle Society to highlight data demonstrating the potential of our therapies to address the underlying causes of neuromuscular diseases to provide functional improvement. See the program and visit us at our booth: https://bit.ly/3WlJwVr #WMS2025

We are pleased to welcome Brian Posner to our Board of Directors. With more than three decades of executive, investment, and board leadership experience, Brian brings a valuable perspective that will help guide Dyne as we work to build the world’s leading neuromuscular disease company and deliver functional improvement for people living with genetically driven neuromuscular diseases. Read about the appointment: https://bit.ly/46ztLQT

Join our team at Dyne Therapeutics! At Dyne, we are on a mission to deliver functional improvement for individuals, families and communities living with neuromuscular diseases. We’re growing and looking for passionate, driven individuals to join us on our mission. Learn how you can be part of this exciting and important journey: https://bit.ly/47GxrhM

What does it mean to be strong? As we honor the Muscular Dystrophy Association’s #MDAstrong campaign this September, we reflect on this big question. Strong, in the neuromuscular community, isn't limited to muscle strength. It's about independence, resilience, clarity in thinking and the initiative to engage meaningfully in daily life. Dyne is grateful to the patient and caregiver community for sharing their strength with us, which guides our development of targeted therapies designed to deliver functional improvement. Strong means being able to do meaningful things: buttoning a shirt, taking one more step, taking fewer pauses during PT or a steadier walk to the mailbox. We support that goal through our advancements towards potentially providing functional improvement. Curious to learn more? https://lnkd.in/gR5qKBc

The Ministry of Health, Labour and Welfare in Japan has granted Orphan Drug designation to DYNE-251 for the treatment of patients with #Duchenne muscular dystrophy (#DMD) who have mutations in the DMD gene that are amenable to exon 51 skipping. This is the latest of similar designations from regulators in the U.S. and Europe for our promising next-generation exon 51 skipping therapy that aims to deliver functional improvement to patients: https://bit.ly/4gM1tG0